Navigation Links
Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
Date:4/3/2013

RARITAN, N.J., April 3, 2013 /PRNewswire/ -- Veridex, LLC (Veridex) announced today that the first study of the company's next-generation circulating tumor cell (CTC) technology, developed in collaboration with researchers at Massachusetts General Hospital (MGH), has been published in Science Translational Medicine.  The collaboration, initially announced in January 2011, has led to the development of a next-generation CTC (or "liquid biopsy") technology that offers enhanced specificity and sensitivity and enables more extensive characterization of captured cells.

The new technology tests for CTCs from the blood of cancer patients using advanced microfluidic separation techniques integrated with innovative magnetic sorting to isolate a broad spectrum of rare circulating cancer cells. This technology will allow physicians to get information about a patient's cancer at the time treatment is being administered, one of the key components to enabling personalized medicine.

Results from the in vitro study showed the integrated system enabled the processing of large blood volumes with high throughput and efficiency, and also allowed for the ability to isolate CTCs from both epithelial and non-epithelial cancers.

In the study, the technology was used to identify the presence of CTCs in patients with cancers of the lung, prostate, pancreas, breast, as well as melanoma.

"Veridex is proud to have introduced CELLSEARCH®, the first and only FDA-cleared CTC test, and we're excited to work with the team at Massachusetts General Hospital on our next-generation test," said Nicholas C. Dracopoli , Ph.D., Vice President and Head of Oncology Biomarkers, Janssen Research & Development, LLC.  "Together, Veridex and the MGH team bring more than 25 years of experience in rare cell technology to this project. We're encouraged by the positive results from this study and the potential role this technology may play in helping to advance physicians' ability to monitor their patients and develop more personalized treatment approaches."

"These results show the possibility of its use for patients in 'real time' as they are receiving treatment. We hope that this next-generation CTC technology will become an everyday tool for doctors treating patients with cancer," said Mehmet Toner , Ph.D., director of the BioMicroElectroMechanical Systems Resource Center in the Massachusetts General Hospital.

How It Works

The system used two modes of immunomagnetic sorting to isolate CTCs: a positive selection mode to identify and tag target CTCs based on expression of the epithelial surface marker EpCAM ("epithelial cell adhesion molecule"), and a negative selection mode, in which the blood sample is depleted of leukocytes by tagging them with specific antibodies. The test's ability to isolate CTCs in this manner allows for RNA-based, single cell molecular characterization and expression analysis of CTCs. It will also allow for the test to be used in a broader range of cancers, including cells undergoing epithelial-mesenchymal transition (EMT) and cancer stem cells.

The technology integrates three sequential processes in a single automated system to capture clinically significant CTCs. First, after whole blood samples have been labeled with magnetic beads, the system separates nucleated cells, including CTCs and white blood cells, from red blood cells and platelets with minimal cell loss. Next, the system aligns nucleated cells in a single file within a sorting channel. Finally, the magnetically tagged cells are deflected into a collection channel for identification. These three integrated functions replace the need for separate cell lysis (break down), centrifugation and sorting steps.

About Circulating Tumor Cells

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

About Veridex, LLC

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value diagnostic oncology products. Veridex's in vitro diagnostic products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care. Veridex's Clinical Research Solutions provide tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies. For more information, visit www.veridex.com.

Media inquiries for Massachusetts General Hospital can be directed to:

Sue McGreevey , smcgreevey@partners.org, 617-724-2764

Katie Marquedant , kmarquedant@partners.org, 617-724-6423

Media Inquiries:
Janssen
Kellie McLaughlin
Phone: 1-908-927-7477
Mobile: 1-609-468-8356

Investor Relations:
Johnson & Johnson
Stan Panasewicz
Phone: 1-732-524-2524
Louise Mehrotra
Phone: 1-732-524-6491


'/>"/>
SOURCE Veridex, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Innovative Research Collaboration to Advance Next-Generation Methods in Peptide Discovery for Cosmeceuticals
2. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
3. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
4. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
5. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
6. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
7. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
8. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
9. Remedy Informatics to Debut SpecimenTrack, Next-Generation Biorepository Software at ISBER 2012 Annual Meeting
10. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
11. The Miami Neuroscience Center at Larkin ofrece esperanza a los diagnosticados con tumores cerebrales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
(Date:4/19/2017)... 19, 2017  New research provides evidence that an old ... to a study released today that will be presented at ... in Boston , April 22 to 28, ... of Parkinson,s disease, the oral drug levodopa has long been ... But as the disease progresses, the effects of the medication ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 21, 2017 , ... Westside Dental Associates and its owner, Dr. ... thirty-two years, Dr. Latner has become one of the Los Angeles area’s premier dentists. ... years with all their dental needs,” said Dr. Latner, who was recently named Chairperson ...
(Date:4/21/2017)... ... 2017 , ... Each year, everyone is urged to give back to the ... look forward to a better future. However, supporting the environment should be an everyday ... can be two to five times more polluted than outdoor air, reports the Environmental ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... familiar? These are five common elements between the Obamacare program that most ... control program which uses Warfarin poison to kill hogs. , Like Obamacare, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana Fiber Network, LLC (IFN), ... service to Tele-Media Solutions. IFN is delivering Multi-Gigabit data rates as an ... Solution’s protect transport with 3GB Dual Access Internet access now available in their ...
(Date:4/21/2017)... ... April 21, 2017 , ... MiracleFeet announced today ... years to help end the disability caused by untreated clubfoot in low-income countries. ... Global Clubfoot Initiative to end disability caused by clubfoot worldwide. , ...
Breaking Medicine News(10 mins):